Artwork

Content provided by Keyvan Koushan, MD, and FRCSC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Keyvan Koushan, MD, and FRCSC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

E15-Serum VEGF Levels in the IVAN Trial- Dr. Usha Chakravarthy

15:16
 
Share
 

Manage episode 214637224 series 2416620
Content provided by Keyvan Koushan, MD, and FRCSC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Keyvan Koushan, MD, and FRCSC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dr. Chakravarthy from Belfast, UK discusses a secondary analysis of the IVAN Trial to compare effects of intravitreal anti-VEGF therapy on serum VEGF levels with possible trends in system adverse events in the context of wet AMD.

Full reference:

Chris A.Rogers, Lauren J.Scott, Barnaby C.Reeves, Susan Downes, Andrew J.Lotery, Andrew D.Dick, Usha Chakravarthy for IVAN trial investigators, Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events, Ophthalmology Retina, Feb. 2018

http://dx.doi.org/10.1016/j.oret.2017.05.015

  continue reading

78 episodes

Artwork
iconShare
 
Manage episode 214637224 series 2416620
Content provided by Keyvan Koushan, MD, and FRCSC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Keyvan Koushan, MD, and FRCSC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Dr. Chakravarthy from Belfast, UK discusses a secondary analysis of the IVAN Trial to compare effects of intravitreal anti-VEGF therapy on serum VEGF levels with possible trends in system adverse events in the context of wet AMD.

Full reference:

Chris A.Rogers, Lauren J.Scott, Barnaby C.Reeves, Susan Downes, Andrew J.Lotery, Andrew D.Dick, Usha Chakravarthy for IVAN trial investigators, Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events, Ophthalmology Retina, Feb. 2018

http://dx.doi.org/10.1016/j.oret.2017.05.015

  continue reading

78 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide